Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Pharmacyclics Incorporated ( PCYC) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Pharmacyclics Incorporated fell $1.64 (-2.1%) to $75.12 on light volume. Throughout the day, 494,469 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 711,300 shares. The stock ranged in price between $75.05-$77.44 after having opened the day at $77.04 as compared to the previous trading day's close of $76.76. Other companies within the Drugs industry that declined today were: Idera Pharmaceuticals ( IDRA), down 9.5%, Chelsea Therapeutics International ( CHTP), down 9.1%, Biocryst Pharmaceuticals ( BCRX), down 8.8%, and Delcath Systems ( DCTH), down 7.9%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $5.33 billion and is part of the health care sector. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 32.8% year to date as of the close of trading on Monday. Currently there are four analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and seven rate it a hold. TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share.